PriceTargets.com logo

OrthoPediatrics - KIDS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 56.86%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$25.50 As of 11/20/2024 01:00 AM ET
▲ +1.18 (4.85%)

This chart shows the closing price for KIDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OrthoPediatrics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIDS

Analyst Price Target is $40.00
▲ +56.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is $40.00, with a high forecast of $50.00 and a low forecast of $28.00. The average price target represents a 56.86% upside from the last price of $25.50.

This chart shows the closing price for KIDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in OrthoPediatrics. This rating has held steady since December 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
10/14/2024Truist FinancialLower TargetHold ➝ Hold$34.00 ➝ $28.00
9/13/2024Truist FinancialReiterated RatingHold ➝ Hold$30.00 ➝ $34.00
9/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$50.00 ➝ $50.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
8/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
8/8/2024Truist FinancialReiterated RatingHold ➝ Hold$35.00 ➝ $30.00
7/16/2024Truist FinancialLower TargetHold ➝ Hold$38.00 ➝ $35.00
5/8/2024Truist FinancialBoost TargetHold ➝ Hold$35.00 ➝ $38.00
5/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$37.00 ➝ $42.00
5/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$50.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$37.00
3/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$50.00
1/25/2024Truist FinancialDowngradeBuy ➝ Hold$39.00 ➝ $31.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$35.00 ➝ $39.00
12/7/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$60.00 ➝ $50.00
11/8/2023Truist FinancialBoost TargetBuy ➝ Buy$31.00 ➝ $35.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$55.00 ➝ $37.00
10/3/2023BTIG ResearchLower TargetBuy ➝ Buy$59.00 ➝ $52.00
9/1/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$60.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$57.00 ➝ $51.00
8/1/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$60.00
8/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$55.00
4/17/2023Needham & Company LLCReiterated RatingBuy$51.00
4/17/2023Truist FinancialBoost TargetBuy$53.00 ➝ $57.00
3/1/2023Needham & Company LLCBoost TargetBuy$50.00 ➝ $51.00
1/31/2023Truist FinancialBoost TargetBuy$47.00 ➝ $56.00
1/10/2023Stifel NicolausLower TargetBuy$52.00 ➝ $50.00
11/2/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $60.00
11/1/2022Piper SandlerLower Target$58.00 ➝ $52.00
11/1/2022Needham & Company LLCLower TargetBuy$59.00 ➝ $50.00
10/17/2022Truist FinancialLower TargetBuy$66.00 ➝ $52.00
8/9/2022BTIG ResearchBoost Target$62.00
8/5/2022Truist FinancialBoost TargetBuy$51.00 ➝ $66.00
7/22/2022Truist FinancialLower Target$51.00
7/18/2022BTIG ResearchLower TargetBuy$65.00 ➝ $61.00
7/18/2022Stifel NicolausLower Target$57.00 ➝ $50.00
6/1/2022JMP SecuritiesReiterated RatingBuy$77.00
5/6/2022Truist FinancialLower Target$70.00 ➝ $54.00
5/5/2022Piper SandlerLower Target$80.00 ➝ $55.00
3/3/2022Needham & Company LLCLower TargetBuy$83.00 ➝ $65.00
12/22/2021BTIG ResearchLower TargetBuy$75.00 ➝ $68.00
12/21/2021Truist FinancialLower TargetBuy$78.00 ➝ $75.00
8/6/2021JMP SecuritiesBoost TargetOutperform$70.00 ➝ $77.00
8/5/2021Piper SandlerBoost TargetOverweight ➝ Overweight$70.00 ➝ $80.00
6/14/2021Needham & Company LLCBoost TargetBuy$70.00 ➝ $77.00
5/7/2021Truist FinancialBoost Target$64.00 ➝ $72.00
5/7/2021JMP SecuritiesBoost TargetOutperform$55.00 ➝ $70.00
5/6/2021Piper SandlerReiterated RatingOverweight$62.00 ➝ $70.00
4/19/2021Truist FinancialBoost Target$54.00 ➝ $64.00
4/6/2021Piper SandlerBoost Target$55.00 ➝ $62.00
10/7/2020BTIG ResearchBoost TargetBuy$54.00 ➝ $57.00
8/5/2020Needham & Company LLCBoost TargetBuy$49.00 ➝ $57.00
6/16/2020Stifel NicolausBoost Target$48.00 ➝ $55.00
6/8/2020BTIG ResearchBoost TargetBuy$48.00 ➝ $54.00
5/14/2020JMP SecuritiesLower TargetMarket Outperform$50.00 ➝ $48.00
5/6/2020BTIG ResearchReiterated RatingBuy$48.00
5/6/2020Needham & Company LLCBoost TargetBuy$46.00 ➝ $49.00
4/3/2020BTIG ResearchLower TargetBuy$50.00 ➝ $48.00
4/2/2020Needham & Company LLCLower TargetBuy$56.00 ➝ $46.00
3/8/2020BTIG ResearchReiterated RatingBuy$50.00
3/6/2020Stifel NicolausBoost TargetBuy$44.00 ➝ $50.00
1/7/2020SunTrust BanksInitiated CoverageBuy$54.00
12/16/2019Piper Sandler CompaniesBoost TargetOverweight$44.00 ➝ $50.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OrthoPediatrics logo
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Read More

Today's Range

Now: $25.50
Low: $23.90
High: $25.53

50 Day Range

MA: $26.79
Low: $22.69
High: $32.28

52 Week Range

Now: $25.50
Low: $22.41
High: $36.23

Volume

244,190 shs

Average Volume

180,505 shs

Market Capitalization

$617.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of OrthoPediatrics?

The following Wall Street research analysts have issued stock ratings on OrthoPediatrics in the last year: JMP Securities, Needham & Company LLC, and Truist Financial Co..
View the latest analyst ratings for KIDS.

What is the current price target for OrthoPediatrics?

0 Wall Street analysts have set twelve-month price targets for OrthoPediatrics in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 56.9%. JMP Securities has the highest price target set, predicting KIDS will reach $50.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $28.00 for OrthoPediatrics in the next year.
View the latest price targets for KIDS.

What is the current consensus analyst rating for OrthoPediatrics?

OrthoPediatrics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KIDS.

What other companies compete with OrthoPediatrics?

Other companies that are similar to OrthoPediatrics include Atrion, Cardiovascular Systems, Cerus, OraSure Technologies and Alphatec. Learn More about companies similar to OrthoPediatrics.

How do I contact OrthoPediatrics' investor relations team?

OrthoPediatrics' physical mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company's listed phone number is (574) 268-6379 and its investor relations email address is [email protected]. The official website for OrthoPediatrics is www.orthopediatrics.com. Learn More about contacing OrthoPediatrics investor relations.